The value of systematic biopsies in screening for prostate cancer with PSA followed by MRI - results from the GOTEBORG prostate cancer screening 2 trial

被引：0

作者：

Kohestani, K. ^{[1
]}

Godtman, Arnsrud R. ^{[1
]}

Axcrona, U. ^{[2
]}

Egevad, L. ^{[3
]}

Hellstrom, M. ^{[4
]}

Khatami, A. ^{[1
]}

Pihl, C-G ^{[5
]}

Stranne, J. ^{[1
]}

Wallstrom, J. ^{[4
]}

Mansson, M. ^{[1
]}

Carlsson, S., V ^{[6
]}

Hugosson, J. ^{[1
]}

机构：

[1] Gothenburg Univ, Sahlgrenska Acad, Dept Urol, Inst Clin Sci, Gothenburg, Sweden

[2] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, Oslo, Norway

[3] Karolinska Inst, Dept Pathol & Oncol, Stockholm, Sweden

[4] Gothenburg Univ, Dept Radiol, Sahlgrenska Acad, Inst Clin Sci, Gothenburg, Sweden

[5] Gothenburg Univ, Sahlgrenska Acad, Dept Pathol, Inst Biomed, Gothenburg, Sweden

[6] Mem Sloan Kettering Canc Ctr, New York Mem, Dept Urol, Surg Urol Serv,Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA

来源：

EUROPEAN UROLOGY | 2022年 / 81卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A0364

引用

页码：S565 / S565

页数：1

共 50 条

[21] Prostate Cancer Screening With PSA, Kallikrein Panel, and MRI The ProScreen Randomized Trial
Auvinen, Anssi
Tammela, Teuvo L. J.
Mirtti, Tuomas
Lilja, Hans
Tolonen, Teemu
Kenttaemies, Anu
Rinta-Kiikka, Irina
Lehtimaeki, Terho
Natunen, Kari
Nevalainen, Jaakko
Raitanen, Jani
Ronkainen, Johanna
van der Kwast, Theodorus
Riikonen, Jarno
Petas, Anssi
Matikainen, Mika
Taari, Kimmo
Kilpelaeinen, Tuomas
Rannikko, Antti S.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (17): : 1452 - 1459
[22] Prostate cancer risk assessment in men with an initial PSA below 3 ng/mL: results from the Goteborg randomized population-based prostate cancer screening trial
Franlund, Maria
Godtman, Rebecka Arnsrud
Carlsson, Sigrid, V
Lilja, Hans
Mansson, Marianne
Stranne, Johan
Hugosson, Jonas
SCANDINAVIAN JOURNAL OF UROLOGY, 2018, 52 (04) : 256 - 262
[23] Prostate cancer screening with MRI does not differ from PSA only for detection but reduces biopsies and overdiagnosis
Wilt, Timothy J.
Dahm, Philipp
ANNALS OF INTERNAL MEDICINE, 2024, 177 (08) : JC94 - JC94
[24] Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial
Murtola, Teemu J.
Tammela, Teuvo L. J.
Maattanen, Liisa
Huhtala, Heini
Platz, Elizabeth A.
Ala-Opas, Martti
Stenman, Ulf-Hakan
Auvinen, Anssi
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (07) : 1650 - 1659
[25] Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
Hugosson, Jonas
Carlsson, Sigrid
Aus, Gunnar
Bergdahl, Svante
Khatami, Ali
Lodding, Par
Pihl, Carl-Gustaf
Stranne, Johan
Holmberg, Erik
Lilja, Hans
LANCET ONCOLOGY, 2010, 11 (08): : 725 - 732
[26] Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial
Nam, Robert
Patel, Chirag
Milot, Laurent
Hird, Amanda
Wallis, Christopher
Macinnis, Patrick
Singh, Mala
Emmenegger, Urban
Sherman, Christopher
Haider, Masoom A.
BMJ OPEN, 2022, 12 (11):
[27] The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial: The prostate cancer screening results in context
Berg, Christine D.
ACTA ONCOLOGICA, 2011, 50 : 12 - 17
[28] Men's estimation of life-time risk of receiving a prostate cancer diagnosis, results from the Goteborg-2 prostate cancer screening trial
Palmstedt, E.
Mansson, M.
Kollberg, Stinesen K.
Carlsson, S.
Wallstrom, J.
Hellstrom, M.
Hugosson, J.
Godtman, Arnsrud R.
EUROPEAN UROLOGY, 2022, 81 : S566 - S566
[29] Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening
Martin, Richard M.
Dixon, Padraig
Turner, Emma
Keeney, Edna
BJU INTERNATIONAL, 2022, 129 (03) : 269 - 270
[30] The use of PSA for screening of prostate cancer
Stenman, Ulf-Hakan
TUMOR BIOLOGY, 2006, 27 : 45 - 45

← 1 2 3 4 5 →